Integral Diagnostics Limited (ASX:IDX) shares were priced at $2.12 on 6 October 2026, down 0.47% on the day, and are down 21.77% over the past twelve months. The medical imaging provider released its FY26 results on 25 August 2026 for the year ended 30 June 2026, consistent with the unaudited preliminary figures it published on 10 August 2026.

Across the broader market, the S&P/ASX 200 Health Care index [XHJ] (INDEXASX: XHJ) stood at 31,982.20, up 0.63% (+200.50 points) as of 6 October, and is down 16% over the past year. Meanwhile, the S&P/ASX 200 stood at 8,735.70, up 0.57% (+49.30 points) at the same time, and is down 2.74% over the year.

Business Model and Operational Footprint

Integral Diagnostics is a provider of medical imaging services across Australia and New Zealand. It employs radiologists and diagnostic imaging specialists under what it calls a medical Leadership model, and it earns Revenue from imaging exams performed across a network of clinics and hospital-based sites, as well as from reporting contracts.

The group's footprint expanded through the Merger with Capitol Health, which was acquired on 20 December 2024, so FY25 comparatives include Capitol only from that date. The company also operates a teleradiology platform, IDXt, which it says has gained scale with the contribution of Capitol radiologists. The company reported group cash of $51.3 million at 30 June 2026 and committed Debt facilities of $467.4 million.

Sector Dynamics

Imaging revenue in Australia is shaped by Medicare policy and referral volumes. Medicare indexation of 2.4% applied from 1 July 2025 to diagnostic imaging services, excluding PET nuclear imaging, and the company noted that MRI de-regulation and the National Lung Cancer Screening Program supported growth in its legacy business.

Referral patterns varied between parts of the group. Organic revenue from all sources in Australia grew 7.4% against Medicare growth of 9.4%, with the legacy IDX Business growing 8.9% and the legacy Capitol business 5.4%, the latter reflecting lower growth in GP attendances and referrals. New Zealand organic revenue grew 2.1% in constant currency. Average fees per exam in Australia increased 6.5%, linked to indexation and a continued move toward CT, MRI and PET modalities.

FY26 Results Update

Revenue and other income was $788.7 million, up 25.6%, and operating EBITDA was $164.8 million, up 30.3%, with the operating EBITDA Margin at 20.9%, up 80 basis points from 20.1%. Operating EBITA was $97.1 million, up 38.8%, and operating NPAT was $47.4 million, up 50.1%. Operating diluted EPS was 12.6 cents, up 23.6%. Statutory NPAT was $22.0 million, compared with $2.8 million in FY25, after $25.4 million of transaction, integration and restructuring related items, net of tax.

Operating free Cash Flow was $106.4 million, up 30.7%, while cash flow conversion eased to 82.0% from 86.5%. Net debt was $298.9 million, up $0.9 million, and the net debt to operating EBITDA ratio was 2.3 times, down from 2.6 times. Equity was $681.5 million, down 1.5%. The weighted average Interest Rate on the core debt Facility fell to 5.36% from 6.24%, with 51.2% of gross debt hedged. Capital Expenditure was $49.8 million, of which $21.0 million related to growth initiatives.

A fully franked final Dividend of 6.0 cents per share was declared, up 50.0%, payable on 2 October 2026, taking the FY26 total to 9.3 cents, compared with 6.5 cents in FY25. The Dividend reinvestment Plan remains available. Annual ongoing merger synergies reached $14.0 million or more, against at least $10.0 million expected at the time of the merger, and procurement savings exceeded initial projections.

Growth Catalysts and Critical Operating Risks

For FY27 and beyond, the company set four areas of focus: core growth and optimisation, network expansion described as disciplined and selective, people and culture, and transformation and innovation. The outcomes it is targeting include sustainable revenue growth, an operating EBITDA margin above 21.0%, increased productivity and capacity, improved patient access and de-gearing. Replacement and growth capital expenditure is expected to be between $50.0 million and $60.0 million, and net debt to EBITDA is projected to continue trending down within a target range of 2.0 to 2.5 times.

Operating risks are visible in the figures. Growth in the legacy Capitol business was below the Medicare growth rate, organic Australian growth of 7.4% sat below Medicare growth of 9.4%, and New Zealand growth was 2.1%. Statutory profit continues to be affected by transaction and integration costs. The company's debt facilities are subject to financial covenants, and while it reported compliance, $117.0 million of its committed facilities remains undrawn subject to covenant compliance. Reimbursement settings, referral volumes and radiologist workforce capacity are further factors that influence an imaging group's results.

The company also reported annual ongoing synergies and procurement benefits from the Capitol merger, a reduced interest rate on its core debt facility, and industry-leading patient satisfaction outcomes. An investor and analyst conference call was held at 11:00am AEDT on the day of the release, led by CEO Jason Martinez and CFO Craig White.

The Bottom Line

Integral Diagnostics reports higher revenue, EBITDA, NPAT, cash flow and dividends for FY26, together with lower Leverage and a lower interest rate, while its share price is down 21.77% over the year. Statutory NPAT of $22.0 million sits well below operating NPAT of $47.4 million because of transaction and integration related items. Margin expansion above 21.0% and further de-gearing are the stated priorities for FY27.